Analysis of vascular Galectin-9 as an immunomodulator of B-cell activity

血管 Galectin-9 作为 B 细胞活性免疫调节剂的分析

基本信息

  • 批准号:
    9981626
  • 负责人:
  • 金额:
    $ 20.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-15 至 2021-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT ABSTRACT Development of effective antibody (Ab) responses is critically dependent on the recruitment of naïve B cells into secondary lymphoid organs and, upon antigen activation, their coordinated differentiation into germinal center (GC) B cells to memory B cells and Ab-producing plasma cells. Knowing which mechanistic factors control B cell subset transition with the therapeutic goal of Ab-boosting or -attenuating activity, however, is still poorly understood. Exciting new published data from our laboratory highlight striking differences in the glycomic signatures of human naïve, GC and memory B cell subsets featured by either i-linear or I-branched poly-N-acetyllactosamines (poly-LacNAcs). Whereas GC B cells express mainly I-branched poly-LacNAcs, naïve/memory B cells display principally i-linear poly-LacNAcs, which enable robust binding to immuno- modulator, galectin (Gal)-9. Gal-9-binding causes downstream inhibition of cell proliferation, activation and signaling related to BCR-engagement while, interestingly, evoking a pro-survival activity. Given the selective Gal-9-binding to naive/memory B cells, we speculate that Gal-9 serves as a physiologic “tuner” of peripheral B cell activation and B cell reactivity. Other key data on the distribution of Gal-9 in “reactive” lymph node (LN)- like tonsil tissue reveal that, while naïve B cells express endogenous Gal-9, Gal-9 expression is strongest on high endothelial venules (HEV). Since HEVs initiate adhesive contact with circulating naïve/memory B cells and are densely packed in the cortex adjacent to B cell follicles, HEVs are strategically poised to elicit Gal-9- dependent adhesion/regulation. The spatial, cellular and functional control of Gal-9 on B cells in lymphoid organs is still unknown and a major gap in the field of galectin immunology. Our guiding hypothesis is that Gal- 9 on HEV can bind circulating naïve/memory B cells and help recruit them into LNs as well as transmit regulatory signals as B cells traverse the endothelium and enter B cell follicles. In this exploratory proposal, we will examine the function of human endothelial cell (EC)-derived Gal-9 on human naïve B cell adhesion and immunoregulation and will assay for B cell homing to peripheral LNs in the presence/absence of Gal-9. The Specific Aims are: 1.) To study Gal-9-dependent vascular EC – B cell adhesive interactions and 2.) To analyze immunoregulatory effects of Gal-9 expressed by cytokine-activated human ECs on human naïve B cells. We will employ our unique experience and innovative primary human cell models, adhesion assays, mutant mice, gene editing methods to study whether Gal-9 on ECs supports naïve B cell adhesion, LN-homing as well as trigger immunoregulatory activity. These exploratory studies directly challenge current dogma that galectins largely function as immunoregulators, offering an alternative role for Gal-9 in facilitating B cell-EC adhesion, LN-homing and in situ peripheral control of B cell activity. Importantly, our findings will reveal novel targets for modulating B cell immunity and provide necessary data for a grant larger in scope.
项目摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES J DIMITROFF其他文献

CHARLES J DIMITROFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES J DIMITROFF', 18)}}的其他基金

Analysis of Glycomic Regulators in Melanoma Progression
黑色素瘤进展中的糖调节因子分析
  • 批准号:
    10086171
  • 财政年份:
    2019
  • 资助金额:
    $ 20.47万
  • 项目类别:
Analysis of Glycomic Regulators in Melanoma Progression
黑色素瘤进展中的糖调节因子分析
  • 批准号:
    10611441
  • 财政年份:
    2019
  • 资助金额:
    $ 20.47万
  • 项目类别:
Analysis of Glycomic Regulators in Melanoma Progression
黑色素瘤进展中的糖调节因子分析
  • 批准号:
    10414886
  • 财政年份:
    2019
  • 资助金额:
    $ 20.47万
  • 项目类别:
Analysis of Glycomic Regulators in Melanoma Progression
黑色素瘤进展中的糖调节因子分析
  • 批准号:
    9886212
  • 财政年份:
    2019
  • 资助金额:
    $ 20.47万
  • 项目类别:
Analysis of vascular Galectin-9 as an immunomodulator of B-cell activity
血管 Galectin-9 作为 B 细胞活性免疫调节剂的分析
  • 批准号:
    9807300
  • 财政年份:
    2019
  • 资助金额:
    $ 20.47万
  • 项目类别:
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
Galectin-1 配体在黑色素瘤进展中的功能分析
  • 批准号:
    8693969
  • 财政年份:
    2013
  • 资助金额:
    $ 20.47万
  • 项目类别:
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
Galectin-1 配体在黑色素瘤进展中的功能分析
  • 批准号:
    9265414
  • 财政年份:
    2013
  • 资助金额:
    $ 20.47万
  • 项目类别:
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
Galectin-1 配体在黑色素瘤进展中的功能分析
  • 批准号:
    8578572
  • 财政年份:
    2013
  • 资助金额:
    $ 20.47万
  • 项目类别:
Mechanistic Analysis of Anti-inflammatory Activity by Fluorosugars
氟糖抗炎活性的机制分析
  • 批准号:
    8007408
  • 财政年份:
    2008
  • 资助金额:
    $ 20.47万
  • 项目类别:
Mechanistic Analysis of Anti-inflammatory Activity by Fluorosugars
氟糖抗炎活性的机制分析
  • 批准号:
    8215806
  • 财政年份:
    2008
  • 资助金额:
    $ 20.47万
  • 项目类别:

相似海外基金

I-Corps: Translation Potential of Peptidic Ensembles as Novel Bio-adhesives
I-Corps:肽整体作为新型生物粘合剂的转化潜力
  • 批准号:
    2409620
  • 财政年份:
    2024
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Standard Grant
Architectural design of active adhesives
活性粘合剂的结构设计
  • 批准号:
    2403716
  • 财政年份:
    2024
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Standard Grant
Design of non-swellable adhesives for brain surgery using cyclodextrin inclusion polymer
使用环糊精包合物聚合物脑外科不可溶胀粘合剂的设计
  • 批准号:
    23H01718
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Meta-material adhesives for improved performance and functionalisation of bondlines
超材料粘合剂可提高粘合层的性能和功能化
  • 批准号:
    EP/W019450/1
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Fellowship
Light-propelled dental adhesives with enhanced bonding capability
具有增强粘合能力的光驱动牙科粘合剂
  • 批准号:
    10741660
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
DMREF: Accelerating the Design of Adhesives with Nanoscale Control of Thermomechanical Properties
DMREF:通过热机械性能的纳米级控制加速粘合剂的设计
  • 批准号:
    2323317
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Continuing Grant
Mag-Cure: A novel method for magnetically induced bonding and de-bonding of thermoset adhesives in the Automotive Industry
Mag-Cure:汽车行业中热固性粘合剂磁感应粘合和脱粘的新方法
  • 批准号:
    10062336
  • 财政年份:
    2023
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Collaborative R&D
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
  • 批准号:
    10677869
  • 财政年份:
    2022
  • 资助金额:
    $ 20.47万
  • 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
  • 批准号:
    10746743
  • 财政年份:
    2022
  • 资助金额:
    $ 20.47万
  • 项目类别:
Enhanced bio-production of difficult to make peptide ingredients for specialty adhesives and personal care
增强用于特种粘合剂和个人护理品的难以制造的肽成分的生物生产
  • 批准号:
    10021363
  • 财政年份:
    2022
  • 资助金额:
    $ 20.47万
  • 项目类别:
    Investment Accelerator
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了